Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

被引：381
作者：
Vilsboll, Tina
Zdravkovic, Milan
Le-Thi, Tu
Krarup, Thure
Schmitz, Ole
Courreges, Jean-Pierre
Verhoeven, Robert
Buganova, Ingrid
Madsbad, Sten
机构：
[1] Gentofte Univ Hosp, Dept Internal Med, DK-2900 Hellerup, Denmark
[2] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
[3] Aarhus Hosp, Aarhus, Denmark
[4] Ctr Hosp Narbonne, Narbonne, France
[5] Gelre Ziekenhuis, Apeldoorn, Netherlands
[6] Dibetol Ambulancia, Zilina, Slovakia
[7] Hvidovre Univ Hosp, Copenhagen, Denmark
来源：
DIABETES CARE | 2007年 / 30卷 / 06期
关键词：
D O I：
10.2337/dc06-2593
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1608 / 1610
页数：3
相关论文
共 11 条
[1]   Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative [J].
Agerso, H ;
Vicini, P .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 19 (2-3) :141-150
[2]  
Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4
[3]   One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes [J].
Degn, KB ;
Juhl, CB ;
Sturis, J ;
Jakobsen, G ;
Brock, B ;
Chandramouli, V ;
Rungby, J ;
Landau, BR ;
Schmitz, O .
DIABETES, 2004, 53 (05) :1187-1194
[4]   Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration [J].
Knudsen, LB ;
Nielsen, PF ;
Huusfeldt, PO ;
Johansen, NL ;
Madsen, K ;
Pedersen, FZ ;
Thogersen, H ;
Wilken, M ;
Agerso, H .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (09) :1664-1669
[5]   Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211) A 12-week, double-blind, randomized, controlled trial [J].
Madsbad, S ;
Schmitz, O ;
Ranstam, J ;
Jakobsen, G ;
Matthews, DR .
DIABETES CARE, 2004, 27 (06) :1335-1342
[6]   Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes [J].
Nauck, M. A. ;
Hompesch, M. ;
Filipczak, R. ;
Le, T. D. T. ;
Zdravkovic, M. ;
Gumprecht, J. .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2006, 114 (08) :417-423
[7]  
PIPER K, 2005, DIABETOLOGIA, pA394
[8]   The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice [J].
Rolin, B ;
Larsen, MO ;
Gotfredsen, CF ;
Deacon, CF ;
Carr, RD ;
Wilken, M ;
Knudsen, LB .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2002, 283 (04) :E745-E752
[9]   GLP-1 derivative liraglutide in rats with β-cell deficiencies:: influence of metabolic state on β-cell mass dynamics [J].
Sturis, J ;
Gotfredsen, CF ;
Romer, J ;
Rolin, B ;
Ribel, U ;
Brand, CL ;
Wilken, M ;
Wassermann, K ;
Deacon, CF ;
Carr, RD ;
Knudsen, LB .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 140 (01) :123-132
[10]   Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J].
Turner, RC ;
Holman, RR ;
Cull, CA ;
Stratton, IM ;
Matthews, DR ;
Frighi, V ;
Manley, SE ;
Neil, A ;
McElroy, K ;
Wright, D ;
Kohner, E ;
Fox, C ;
Hadden, D ;
Mehta, Z ;
Smith, A ;
Nugent, Z ;
Peto, R ;
Adlel, AI ;
Mann, JI ;
Bassett, PA ;
Oakes, SF ;
Dornan, TL ;
Aldington, S ;
Lipinski, H ;
Collum, R ;
Harrison, K ;
MacIntyre, C ;
Skinner, S ;
Mortemore, A ;
Nelson, D ;
Cockley, S ;
Levien, S ;
Bodsworth, L ;
Willox, R ;
Biggs, T ;
Dove, S ;
Beattie, E ;
Gradwell, M ;
Staples, S ;
Lam, R ;
Taylor, F ;
Leung, L ;
Carter, RD ;
Brownlee, SM ;
Fisher, KE ;
Islam, K ;
Jelfs, R ;
Williams, PA ;
Williams, FA ;
Sutton, PJ .
LANCET, 1998, 352 (9131) :837-853
12